TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW 31
1.4 CURRENCY AND PRICING 33
1.5 LIMITATIONS 33
1.6 MARKETS COVERED 33
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 DBMR TRIPOD DATA VALIDATION MODEL 39
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.6 MULTIVARIATE MODELLING 43
2.7 MARKET APPLICATION COVERAGE GRID 44
2.8 PRODUCT LIFELINE CURVE 45
2.9 DBMR MARKET POSITION GRID 46
2.10 VENDOR SHARE ANALYSIS 47
2.11 SECONDARY SOURCES 48
2.12 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PESTEL ANALYSIS 52
4.2 PORTER FIVE FORCES 53
4.3 PATENT ANALYSIS 54
4.4 PATIENT FLOW DIAGRAM 55
4.5 KEY PRICING STRATEGIES 56
4.6 FUTURE THERAPIES 57
4.7 KEY PATIENT ENROLLMENT STRATEGIES 58
5 PIPELINE ANALYSIS 59
6 EPIDEMIOLOGY 60
7 INDUSTRY INSIGHTS 61
8 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET: REGULATIONS 62
9 MARKET OVERVIEW 65
9.1 DRIVERS 67
9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 67
9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 67
9.1.3 AWARENESS REGARDING THE DISEASE 68
9.2 RESTRAINTS 68
9.2.1 STRICT REGULATORY GUIDELINES 68
9.2.2 HIGH TREATMENT COSTS 68
9.3 OPPORTUNITIES 69
9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 69
9.3.2 INCREASING HEALTHCARE FACILITIES 69
9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 70
9.4 CHALLENGES 70
9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 70
9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 71
10 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 72
10.1 OVERVIEW 73
10.2 TREATMENT 76
10.2.1 MEDICATIONS, BY TYPE 76
10.2.1.1 CORTICOSTEROIDS 77
10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 77
10.2.1.2.1 AZATHIOPRINE 78
10.2.1.2.2 MYCOPHENALATE MOFETIL 78
10.2.1.2.3 METHOTREXATE 78
10.2.1.2.4 CYCLOPHOSPHAMIDE 78
10.2.1.2.5 MIZORIBINE 78
10.2.1.2.6 OTHERS 78
10.2.1.3 ANTI- INFLAMMATORY AGENTS 78
10.2.1.3.1 DIAMINODYPHENYL SULFONE 79
10.2.1.3.2 TETRACYCLINE 79
10.2.1.3.3 OTHERS 79
10.2.1.4 BIOLOGICS 79
10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 79
10.2.1.6 ANTIBIOTICS 79
10.2.1.7 ANTIFUNGALS 79
10.2.1.8 ANTIVIRALS 79
10.2.1.9 OTHER MEDICATIONS 79
10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 79
10.2.2.1 ORAL 80
10.2.2.2 TOPICAL 80
10.2.2.3 PARENTERAL 80
10.2.2.4 OTHERS 80
10.2.3 MEDICATIONS, BY DRUG TYPE 80
10.2.3.1 GENERIC 81
10.2.3.2 BRANDED 81
10.3 DIAGNOSIS 81
10.3.1 SKIN BIOPSY 82
10.3.2 BLOOD TEST 82
10.3.3 ENDOSCOPY 82
11 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 83
11.1 OVERVIEW 84
11.2 ADULTS 87
11.3 GERIATRIC 88
11.4 PEDIATRIC 89
12 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER 90
12.1 OVERVIEW 91
12.2 HOSPITALS 94
12.3 SPECIALTY CLINICS 94
12.4 RESEARCH INSTITUTES 95
12.5 OTHERS 96
13 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 97
13.1 OVERVIEW 98
13.2 HOSPITALS PHARMACY 101
13.3 RETAIL PHARMACY 101
13.4 ONLINE PHARMACY 102
14 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, BY REGION 103
14.1 MIDDLE EAST AND AFRICA 104
14.1.1 SAUDI ARABIA 112
14.1.2 EGYPT 116
14.1.3 U.A.E. 120
14.1.4 SOUTH AFRICA 124
14.1.5 ISRAEL 128
14.1.6 REST OF MIDDLE EAST AND AFRICA 131
15 MIDDLE EAST & AFRICA PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 132
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 132
16 SWOT ANALYSIS 133
17 COMPANY PROFILE 134
17.1 ABBVIE INC. 134
17.1.1 COMPANY SNAPSHOT 134
17.1.2 REVENUE ANALYSIS 134
17.1.3 COMPANY SHARE ANALYSIS 135
17.1.4 PRODUCT PORTFOLIO 135
17.1.5 RECENT DEVELOPMENTS 136
17.2 MERCK & CO., INC., 137
17.2.1 COMPANY SNAPSHOT 137
17.2.2 REVENUE ANALYSIS 137
17.2.3 COMPANY SHARE ANALYSIS 138
17.2.4 PRODUCT PORTFOLIO 138
17.2.5 RECENT DEVELOPMENT 138
17.3 SANOFI 139
17.3.1 COMPANY SNAPSHOT 139
17.3.2 REVENUE ANALYSIS 139
17.3.3 COMPANY SHARE ANALYSIS 140
17.3.4 PRODUCT PORTFOLIO 140
17.3.5 RECENT DEVELOPMENT 140
17.4 REGENERON PHARMACEUTICALS INC. 141
17.4.1 COMPANY SNAPSHOT 141
17.4.2 REVENUE ANALYSIS 141
17.4.3 COMPANY SHARE ANALYSIS 142
17.4.4 PRODUCT PORTFOLIO 142
17.4.5 RECENT DEVELOPMENT 142
17.5 NOVARTIS AG 143
17.5.1 COMPANY SNAPSHOT 143
17.5.2 REVENUE ANALYSIS 143
17.5.3 COMPANY SHARE ANALYSIS 144
17.5.4 PRODUCT PORTFOLIO 144
17.5.5 RECENT DEVELOPMENT 144
17.6 AMGEN INC. 145
17.6.1 COMPANY SNAPSHOT 145
17.6.2 REVENUE ANALYSIS 145
17.6.3 PRODUCT PORTFOLIO 146
17.6.4 RECENT DEVELOPMENTS 146
17.7 ASTRAZENECA 147
17.7.1 COMPANY SNAPSHOT 147
17.7.2 REVENUE ANALYSIS 147
17.7.3 COMPANY SHARE ANALYSIS 148
17.7.4 PRODUCT PORTFOLIO 148
17.7.5 RECENT DEVELOPMENTS 149
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 150
17.8.1 COMPANY SNAPSHOT 150
17.8.2 REVENUE ANALYSIS 150
17.8.3 PRODUCT PORTFOLIO 151
17.8.4 RECENT DEVELOPMENT 151
17.9 CELLTRION HEALTHCARE CO., LTD 152
17.9.1 COMPANY SNAPSHOT 152
17.9.2 REVENUE ANALYSIS 152
17.9.3 PRODUCT PORTFOLIO 153
17.9.4 RECENT DEVELOPMENTS 153
17.10 F. HOFFMANN- LA ROCHE LTD. 154
17.10.1 COMPANY SNAPSHOT 154
17.10.2 REVENUE ANALYSIS 154
17.10.3 PRODUCT PORTFOLIO 155
17.10.4 RECENT DEVELOPMENT 155
17.11 FRESENIUS KABI AG 156
17.11.1 COMPANY SNAPSHOT 156
17.11.2 REVENUE ANALYSIS 156
17.11.3 PRODUCT PORTFOLIO 157
17.11.4 RECENT DEVELOPMENT 157
17.12 GSK PLC 158
17.12.1 COMPANY SNAPSHOT 158
17.12.2 REVENUE ANALYSIS 158
17.12.3 PRODUCT PORTFOLIO 159
17.12.4 RECENT DEVELOPMENT 159
17.13 JOHNSON & JOHNSON SERVICES, INC. 160
17.13.1 COMPANY SNAPSHOT 160
17.13.2 REVENUE ANALYSIS 160
17.13.3 COMPANY SHARE ANALYSIS 161
17.13.4 PRODUCT PORTFOLIO 161
17.13.5 RECENT DEVELOPMENT 161
17.14 LILLY 162
17.14.1 COMPANY SNAPSHOT 162
17.14.2 REVENUE ANALYSIS 162
17.14.3 PRODUCT PORTFOLIO 163
17.14.4 RECENT DEVELOPMENT 163
17.15 PFIZER INC. 164
17.15.1 COMPANY SNAPSHOT 164
17.15.2 REVENUE ANALYSIS 164
17.15.3 PRODUCT PORTFOLIO 165
17.15.4 RECENT DEVELOPMENT 165
17.16 RAKSHIT DRUGS PVT. LTD 166
17.16.1 COMPANY SNAPSHOT 166
17.16.2 PRODUCT PORTFOLIO 166
17.16.3 RECENT DEVELOPMENT 166
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 167
17.17.1 COMPANY SNAPSHOT 167
17.17.2 REVENUE ANALYSIS 167
17.17.3 PRODUCT PORTFOLIO 168
17.17.4 RECENT DEVELOPMENT 168
17.18 ZYDUS GROUP 169
17.18.1 COMPANY SNAPSHOT 169
17.18.2 REVENUE ANALYSIS 169
17.18.3 PRODUCT PORTFOLIO 170
17.18.4 RECENT DEVELOPMENT 170
18 QUESTIONNAIRE 171
19 RELATED REPORTS 173

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.